Analyst Articles

On Friday morning we made a change to our portfolio. We removed First Majestic Silver (NYSE: AG), and replaced it with BYD Company (OTCMKTS: BYDDF). While we think AG still retains a good production growth profile, our mission is to follow the best funds we can find. Our reference fund… Read More

Sell First Majestic Silver (NYSE: AG). Buy BYD Company (OTCMKTS: BYDDF). While First Majestic Silver remains, in our opinion, one of the better pure-play silver miners out there, our reference fund no longer favors it. Following our mission, today we remove it from our portfolio. In its place we welcome… Read More

On Wednesday morning, we closed out our two open positions, the VanEcks Vectors Gold Miners ETF (NYSE: GDX) December 15, 2017 $23 put and the PowerShares DB U.S. Dollar Index Bullish Fund (NYSE: UUP). Our gold stock indicator improved to a “-1” reading and our dollar indicator dropped to “+1.”… Read More

Sell to close the PowerShares DB U.S. Dollar Index Bullish Fund (NYSE: UUP) December 15, 2017 $25 call option. Sell to close the VanEck Vectors Gold Miners ETF (NYSE: GDX) December 15, 2017 $23 put option. We recommend taking the modest gains… Read More

Heading into this week’s Federal Open Market Committee meeting, most expected another rate hike, and the Fed delivered. With one dissenter, the committee voted to up the target federal funds rate to a range of 1 to 1.25 percent. This marks the fourth quarter-percentage point rate increase since the Financial… Read More

On Wednesday, we recommended buying to open the PowerShares DB US Dollar Index Bullish Fund (NYSE: UUP) December 15, 2017 $25 call option. Our dollar indicator became bullish enough to warrant going long the dollar.  At the same time, we recommended buying to close the CurrencyShares Japanese Yen Trust… Read More

Sell to close the CurrencyShares Japanese Yen Trust (NYSE: FXY) July 21, 2017 $90 call option. Buy to open the PowerShares DB U.S. Dollar Index Bullish Fund (NYSE: UUP) December 15, 2017 $25 call option. We suggest paying no more than 60 cents per contract. We… Read More

Biotech Theravance Biopharma (Nasdaq: TBPH) this week reported another piece of good clinical data. The company reported that multiple studies conducted on VIBATIV—currently its only marketed drug—showed superior in vitro potency for VIBATIV against the S. aureus pathogens compared to other commercially available antibiotics. VIBATIV is already approved to treat S. aureus, but the company hopes the studies will differentiate it from competing antibiotics. Read More